Stock listing
OTC:KLDO Kaleido Biosciences, Inc. Stock
Follow Kaleido Biosciences, Inc. into a list and get an email when it puts out news.
Share price · OTC:KLDO
$0.0001 USD 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.0001 – $0.0001 USDNov 20, 2026
- Volume
- 3,064 sharesNov 20, 2026
- Market cap
- $4,262 USDAt the close on Nov 20, 2026 · price × 42.62M shares outstanding
- 52-week range
- $0.0001 – $0.2000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $0 USDMedian day 200 shares · 26 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:KLDO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 3,064 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0002 | $0.0001 | 824 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,600 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 200 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,075 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 4,020 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 4,496 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 21,615 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,200 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,700 | |
| $0.0001 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0001 | 1,700 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,500 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 715 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,641 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 670 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,222 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 11,167 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 200 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 525 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,500 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0100 | $0.0001 | 2,740 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 14,742 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 202 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 220 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 100 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 140 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 940 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 400 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 653 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,679 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,312 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 260 |
- Ticker
- OTC:KLDO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Kaleido Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 9 decks · latest Oct 5, 2021
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.00
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kaleido Biosciences, Inc. · OTC:KLDO | US$4,262 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.00 |
| Chimeric Therapeutics Limited · ASX:CHM | US$293,496 | −US$220,705 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| ZyVersa Therapeutics, Inc. · OTC:ZVSA | US$810 | US$1.20B | n/a | n/a | n/a | n/a | n/a | n/a | -0.56 |
| Median of the others | US$164,053 | US$159,190 | 18.5× | 0.1× | −382.1% | 1.3× | 1.14 |
Events
| Quarter | Results |
|---|---|
| Quarter to Jun 30, 2022 | Aug 10, 2022 |
| Q1 2022 | Apr 1, 2022 · Before open |
| Q4 2021 | Mar 29, 2022 |
| Q3 2021 | Nov 1, 2021 · Before open |
| Q2 2021 | Aug 11, 2021 · Before open |
| Q1 2021 | May 4, 2021 · Before open |
| Q4 2020 | Mar 3, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (October 2021) | Investor day | 40 slides | Oct 5, 2021 |
| Investor Presentation (June 2021) | Investor deck | 38 slides | Jun 17, 2021 |
| Technical Presentation (March 2021) | Technical | 21 slides | Mar 24, 2021 |
| Investor Presentation (January 2021) | Investor deck | 38 slides | Jan 20, 2021 |
| Investor Presentation (May 2020) | Investor deck | 43 slides | May 14, 2020 |
| Investor Presentation (December 2019) | Investor deck | 32 slides | Dec 12, 2019 |
| Investor Presentation (October 2019) | Investor deck | 29 slides | Oct 30, 2019 |
| Investor Presentation (August 2019) | Investor deck | 30 slides | Aug 1, 2019 |
| Investor Presentation (April 2019) | Investor deck | 31 slides | Apr 8, 2019 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.10M | 975.0K | 0 | 0 | 0 | 0 | |
| Cost of revenue | 2.36M | 56.0K | 1.32M | 0 | 0 | 0 | |
| Gross profit | -1.25M | 975.0K | -1.32M | 0 | 0 | 0 | |
| Research and development | 67.8M | 56.0M | 64.2M | 42.1M | 21.0M | 7.86M | |
| Selling, general and administrative | 21.0M | 23.9M | 22.4M | 18.6M | 6.04M | 1.57M | |
| Operating income | -87.7M | -78.9M | -86.7M | -60.7M | -27.0M | -9.44M | |
| Depreciation and amortization | 228.5K | 2.36M | 1.82M | 1.32M | 792.0K | 316.0K | 99.0K |
| EBITDA | -85.3M | -77.1M | -85.3M | -59.9M | -26.7M | -9.34M | |
| Interest expense | 2.84M | 2.80M | 977.0K | 1.00M | 435.0K | 141.0K | |
| Income before tax | -90.3M | -81.6M | -86.3M | -61.7M | -27.6M | -9.69M | |
| Income tax | 2.98M | -1.82M | -1.32M | -56.0K | -94.0K | 139.0K | |
| Net income | -90.3M | -79.8M | -85.0M | -61.7M | -27.6M | -9.69M | |
| Earnings per share, basic | -2.16 | -2.39 | -3.31 | -2.10 | -1.23 | -0.43 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 38.5M | 46.2M | 71.2M | 76.1M | 28.5M | 2.73M | |
| Receivables | 934.0K | 5.00K | 45.0K | 1.50M | |||
| Current assets | 42.3M | 48.7M | 73.3M | 76.2M | 28.6M | 4.36M | |
| Property, plant and equipment | 5.67M | 8.46M | 6.74M | 4.69M | 1.98M | 513.0K | |
| Total assets | 50.1M | 59.3M | 82.3M | 85.3M | 30.7M | 4.99M | |
| Accounts payable | 5.67M | 5.39M | 2.02M | 3.44M | 864.0K | 872.0K | |
| Current liabilities | 29.7M | 16.7M | 10.4M | 11.3M | 3.85M | 1.21M | |
| Long-term debt | 5.55M | 18.4M | 20.4M | 14.8M | 14.8M | 4.95M | |
| Total debt | 21.7M | 21.0M | 20.5M | 14.9M | 14.9M | 4.95M | |
| Total liabilities | 39.5M | 38.8M | 33.4M | 27.1M | 74.4M | 21.9M | |
| Shareholders' equity | 10.6M | 20.5M | 48.9M | 58.2M | -43.7M | -16.9M | |
| Shares outstanding | 41.9M | 41.9M | 33.5M | 25.7M | 29.4M | 22.4M | 22.4M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -77.1M | -61.5M | -75.8M | -46.3M | -22.5M | -9.35M | |
| Capital spending | 0 | -1.13M | -4.02M | -3.59M | -3.00M | -1.41M | -195.0K |
| Free cash flow | -78.2M | -65.5M | -79.4M | -49.3M | -23.9M | -9.54M | |
| Cash from investing | -691.0K | -4.02M | -3.59M | -3.00M | -1.41M | -195.0K | |
| Cash from financing | 70.0M | 40.4M | 74.6M | 98.9M | 49.7M | 10.9M | |
| Share buybacks | -339 | 40.5M | 68.4M | 100.9M | 39.9M | 5.99M | |
| Change in cash | -7.75M | -25.1M | -4.74M | 49.6M | 25.8M | 1.39M |
Cap table
Built by 6ix from Kaleido Biosciences, Inc.’s releases
- Common shares
- 42,622,559
- Fully diluted
- 42,622,559
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 42,622,559 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 42,622,559 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Noubar Afeyan Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Co-founder, Chairman, Moderna, Flagship Pioneering · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past) | Director · Feb 27, 2019 – Mar 4, 2019 · Past |
| Michael W. Bonney Other companies: Immunic, Inc. (Chair · Since at least May 16, 2026); Autolus Therapeutics plc (Member of the Compensation Committee · Since at least Mar 18, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Dec 17, 2014); Bristol-Myers Squibb Company (Director · Nov 20, 2019 – Jun 30, 2021 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 1, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 14, 2018 – Jun 11, 2019 · Past); Sarepta Therapeutics, Inc. (Director · Dec 4, 2017 – Feb 28, 2020 · Past); Global Blood Therapeutics Inc (Director · Feb 8, 2016 – Jun 16, 2016 · Past); Celgene Corporation (Director · Apr 14, 2015 – Nov 20, 2019 · Past); NPS Pharmaceuticals Inc (Director · Jan 17, 2006 – Feb 21, 2015 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past) | Director · Feb 27, 2019 – Jun 30, 2021 · Past |
| Alison Frances Lawton Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Dec 22, 2020); Spyre Therapeutics, Inc. (Director · Dec 15, 2020 – Jun 22, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Oct 5, 2020 – Jun 10, 2024 · Past); CoLucid Pharmaceuticals Inc (Director · Mar 11, 2016 – Mar 1, 2017 · Past); Tempest Therapeutics, Inc. (Chief Operating Officer · Jan 21, 2013 – Jun 7, 2013 · Past); Verastem, Inc. (Director · Nov 26, 2012 – Jun 21, 2019 · Past); Cubist Pharmaceuticals Inc (Director · Feb 15, 2012 – Jan 21, 2015 · Past) | See Remarks, Director · Feb 27, 2019 – Apr 15, 2020 · Past |
| Katharine Knobil Other companies: Korro Bio, Inc. (Director · Since at least Aug 26, 2024); Pliant Therapeutics, Inc. (Director · Since at least Sep 14, 2022); Marker Therapeutics, Inc. (Chief Medical Officer, Altesa BioSciences, Inc. · Since at least Dec 8, 2021); Arena Pharmaceuticals Inc (Director · Jun 12, 2020 – Mar 11, 2022 · Past) | Chief Medical Officer · Feb 27, 2019 – Oct 15, 2020 · Past |
| Kyriazi Theo Melas Other companies: Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 8, 2023 · Past); Bausch Health Companies Inc. (Director · Sep 28, 2010 – May 2, 2016 · Past); Valeant Pharmaceuticals International Inc (Director · Mar 30, 2006 – Sep 28, 2010 · Past) | Director · Jul 11, 2019 – Jun 30, 2021 · Past |
| Anne Prener Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 25, 2026); Damora Therapeutics, Inc. (Director · Since at least Jan 8, 2021); Rubius Therapeutics Inc (Director · Dec 17, 2019 – May 12, 2022 · Past) | Director · Apr 1, 2020 – Jun 30, 2021 · Past |
| Anthony G Quinn Other companies: Generation Bio Co (Director · Since at least Jun 11, 2020); Spyre Therapeutics, Inc. (President & CEO, Director · Apr 6, 2016 – Mar 16, 2022 · Past); Synageva BioPharma Corp (EVP, CMO, & Head of R&D · Nov 2, 2011 – Jun 22, 2015 · Past) | Director · Feb 27, 2019 – Jun 30, 2021 · Past |
| Bonnie Bassler Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 22, 2021); Royalty Pharma plc (Board Member · Since at least Jun 15, 2020); Regeneron Pharmaceuticals, Inc. (Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University · Since at least Sep 9, 2016) | Director · Feb 27, 2019 – Jun 30, 2021 · Past |
| John Sculley Other companies: Celularity Inc. (Director · Jul 16, 2021 – Jun 14, 2023 · Past); Zeta Global Holdings Corp. (Director · Jun 9, 2021 – Jun 9, 2025 · Past); Decoy Therapeutics Inc. (Director · Jan 28, 2015 – Jun 8, 2016 · Past) | Director · Feb 27, 2019 – Feb 27, 2019 · Past |
| Joshua Brumm Other companies: Crescent Biopharma, Inc. (Chief Executive Officer · Since at least Jun 13, 2025); Dyne Therapeutics, Inc. (CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past) | See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past |
All 20 people
| Person | Seat |
|---|---|
| William Duke Other companies: Invivyd, Inc. (Chief Financial Officer · Since at least Sep 1, 2023); Apexigen Inc. (Chief Financial Officer · Jul 29, 2022 – Aug 23, 2023 · Past); Pulmatrix, Inc. (Chief Financial Officer · Jun 24, 2015 – May 16, 2019 · Past) | Chief Financial Officer · Nov 22, 2019 – Jan 14, 2022 · Past |
| Richard William Scalzo Other companies: Crescent Biopharma, Inc. (Chief Financial Officer · Since at least Jun 13, 2025); Dyne Therapeutics, Inc. (SVP, Head of Finance & Admin. · Sep 16, 2020 – Mar 11, 2025 · Past) | Principal Accounting Officer · Oct 11, 2019 – Oct 11, 2019 · Past |
| Alison S Long Other companies: Taysha Gene Therapies, Inc. (Director · Since at least Nov 1, 2023) | Chief Medical Officer · Dec 15, 2021 – Jan 14, 2022 · Past |
| Daniel L Menichella Other companies: Talecris Biotherapeutics Holdings Corp (Sr. VP, Business Development · Sep 30, 2009 – Jun 1, 2011 · Past) | Chief Executive Officer, Director · Oct 13, 2020 – Jan 14, 2022 · Past |
| Geoffrey von Maltzahn Other companies: Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Feb 8, 2021 · Past) | Director · Feb 27, 2019 – Jun 30, 2021 · Past |
| Jean K Mixer Other companies: NxStage Medical Inc (Director · Feb 21, 2019 – Feb 21, 2019 · Past) | Director · Sep 30, 2019 – Jun 30, 2021 · Past |
| Jerald Korn Other companies: Epizyme Inc (Chief Operating Officer · Mar 21, 2022 – Aug 12, 2022 · Past) | COO & General Counsel · Jul 22, 2019 – Feb 28, 2022 · Past |
| Grady Burnett | Director · Feb 27, 2019 – Jun 30, 2021 · Past |
| Jonathan McIntyre | Director · Feb 27, 2019 – Feb 27, 2019 · Past |
| Vlieg Johan van Hylckama | Chief Scientific Officer · May 5, 2021 – Feb 28, 2022 · Past |
Log in to ask 6ix AI your own questions about Kaleido Biosciences, Inc.